HPV Vaccine Study for Chinese Women with or without Prior Cervarix
Part of Infections clinical trials.
This study tests a new HPV vaccine (V503, known as Gardasil 9) in Chinese women who either previously received the bivalent HPV vaccine (Cervarix) more than a year ago or never had any HPV vaccine. The goal is to see if this vaccine can effectively prevent HPV-related diseases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be female
- You must be between 20 and 45 years old (as per typical study age range, but not explicitly stated here)
- You must have either received the bivalent HPV vaccine (Cervarix) more than a year ago, or have never received any HPV vaccine
- You must not have a history of abnormal Pap tests (such as LSIL, HSIL, ASC-US, ASC-H) or cervical biopsy showing CIN, AIS, or cervical cancer
- You must not have a history of genital warts, vulvar, vaginal, or anal precancerous changes or cancers
- You must not have a history of a positive HPV test
- You must not have a weakened immune system or be on immunosuppressive therapy (with some exceptions for inhaled, nasal, or topical steroids)
- You must not have received immune globulin or blood products (with some exceptions) or participated in other HPV vaccine trials
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.
This trial tests whether different batches of the HPV 9-valent vaccine work consistently. It's for Chinese women aged 18 to 30 who have not had any HPV vaccine or abnormal cervical screening results.
This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.
This trial studies whether a quadrivalent HPV vaccine is safe and helps the body build protection (immunity) against HPV. It enrolls healthy Chinese females who are not already treated for HPV-related infection.
This study tests a 9-valent HPV vaccine (protects against 9 types of human papillomavirus) in women who have already completed a previous HPV vaccine series. Researchers will check how safe the new vaccine is and how well your immune system responds to it.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
Hear when a new Papillomavirus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.